Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top London based Founder operating in the Health Diagnostics space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Siro Perez
Co-Founder & CEO of Molecular Warehouse
Follow Siro Perez:
About IP Group, Kira Biotech, Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
_______
Nikita Alexandrov
Co-Founder of Molecular Warehouse
Nikita brings advanced expertise in instrumentation and high throughput research techniques. Prior to MW, he founded Permanetix Corporation, developing technology in the field of Fusion energy. Previously, he was the first employee in the aerospace materials testing start-up XEEL Corp, where he developed tools and techniques for high energy testing of space flight hardware for NASA. Nikita graduated from Auburn University (USA) in 2012, with a degree in chemistry, focusing on analytical chemistry, where he received his own lab to conduct chemical plasma reactor research and development. Nikita has an MBA from the University of Alabama (USA).
Follow Nikita Alexandrov:
About Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
Rafael López Schietekat
Founder & Managing Director of Diagnostikare
Follow Rafael López Schietekat:
About Diagnostikare: The first data-driven patient-centric virtual primary care platform in Mexico.
Matteo Berlucchi
CEO & Co-Founder of Healthily by Your.MD
Matteo’s digital career spans 20 years, during which he has conceived, built and launched several successful companies and services both online and on mobile. Most recently, Matteo was Chief Digital Officer at Northern & Shell, the largest independent media company in the UK,where he grew traffic and revenues 4-fold in just 12 months. Matteo was also the founder and CEO of aNobii, the ebook platform funded by Penguin Random House, HarperCollins which was acquired by Sainsbury’s in 2012. Matteo founded Livestation, the leading service for live TV news online and the first company in the world to stream live TV on iPhones. Livestation is also the winner of the Guardian Digital Innovation Award 2008. Prior to this, Matteo was CEO and co-founder of Skinkers, a software company, which defined the market for desktop widgets and the winner of several international innovation awards in the digital space. Matteo started his career by launching the first online property system in Europe in 1995.
Follow Matteo Berlucchi:
About Healthily by Your.MD, Vini Italiani: Healthily is the world’s first medically approved self-care app designed around you.
Aris Papageorghiou
Co-Founder & CMO of Intelligent Ultrasound
Aris Papageorghiou is the Professor of Fetal Medicine at University of Oxford.
Follow Aris Papageorghiou:
About Intelligent Ultrasound, Royal College of Obstetricians and Gynaecologists, St Georges University Hospitals NHS Foundation Trust, Ultrasound Diagnostic Services, University of Oxford: Intelligent Ultrasound develops software that improves the quality, reliability, and diagnostic power of medical ultrasound.
Aron Rachamim
Founder & CEO of Senzo
Aron Rachamim is committed to changing the world by putting healthcare information into everyone’s hands. A serial entrepreneur, scientist, and experienced leader, Aron aims to apply pioneering technologies to improve people’s quality of life. His expertise and passion for the science of microfluidics builds on his background in life sciences, physics, and engineering. His company Orphidia intends to transform the world of medical diagnostics. Aron launched Orphidia in 2013 to provide affordable, point-of-care diagnostics that allow everyone to know their health. Orphidia has advanced the state-of-the-art with microfluidic-based medical diagnostics that are minimally invasive, replacing venous blood draws from a phlebotomist with a simple fingerstick that anyone can perform. Aron is a serial entrepreneur, whose background combines a PhD from the University of Cambridge and a focus on microfluidics and biotechnology with strong experience in professional management. At Protein Logic, a spin-out from Cambridge University that raised more than £3 million in initial funding to develop proprietary biomarker technology for the diagnosis and prediction of diseases, he served as COO. At WiseMed, where he was Co-founder, his team developed crowdsourced medical diagnostic technology as an affordable solution for improving healthcare in the developing world. Now, at Orphidia, Aron is providing the vision and leadership that will usher in the next generation of medical diagnostics, empowering everyone to know their health.
Follow Aron Rachamim:
About Senzo: Senzo is a deep-tech bio-med company developing testing products and IP.
Melinda Nicci
Founder and CEO of Baby2Body
Melinda is founder and CEO of Body Collective (Baby2body) the award- winning, wellness company for women.
She is a Sports and Exercise Psychologist, author of two bestselling books, is a regular contributor on the BBC, and sits on numerous boards as a NED, including The ICE List and Team GB (Olympic and Para-olympics snow-sport teams).
Melinda was named the UKBAA High Growth Founder of the year 2019/20, and has won numerous accolades and awards for entrepreneurship, including being named in the UK list of the Most Influential Women in Tech for 4 years running.
A serial entrepreneur, she founded and sold her first business at the age of 25 in South Africa, and held the position of Senior Director for Consumer health Innovation at Philips in Amsterdam. Melinda brings her passion for sport, performance and wellness to the numerous companies she advises and has created a global business with Body Collective, helping millions of women all over the world to live healthier and happier lives.
Follow Melinda Nicci:
About Baby2Body, GB Snowsport, ICE List: Baby2Body is a fully automated health, fitness and wellbeing coaching platform for pregnant women and mothers.
Abdullah Sabyah
Founder and CEO of Rightangled
A scientist-entrepreneur and a healthcare professional, also a member of the British Heart Foundation Alliance, a member of the Clinical Pharmacogenomics Implementation Consortium in the US, and the inventor of a patent pending-technology for nucleic acid testing on a lateral flow assay (the patent is for a technology to detect DNA sequences in real-time).
Follow Abdullah Sabyah:
About Rightangled: Medtech specialised in Genetics, Blood and infection testing. Service is delivers through a platform that connects users with specialists.
Andrea Spezzi
Chief Medical Officer & Co-Founder of Orchard Therapeutics
Andrea is a co-founder of Orchard Therapeutics and brings to the company extensive experience and expertise in the development and execution of all aspects of clinical development and particularly in paediatric rare diseases. Prior to joining Orchard Therapeutics, Andrea served as VP and Medicine Development Leader at GSK Rare Diseases Unit. Previous to joining the GSK Rare Diseases Unit, Andrea was Senior Medical Director at the Immune Inflammation Discovery Performance Unit. Before GSK, Andrea was Global Medical Director R&D at Takeda in the metabolic and cardiovascular area and in charge of the paediatric developments for Takeda Europe R&D. Before that, she worked as Research Physician at Hammersmith Medicines Research. Before moving to the pharmaceutical industry Andrea practiced as a paediatrician for 12 years in Argentina, Spain and UK. Andrea obtained her medical degree from the University of Buenos Aires (UBA) and completed residency in paediatrics and post graduate training in paediatric immunology at the Dr Elizalde Children’s Hospital in Buenos Aires, Argentina. She obtained a Specialist in Pharmaceutical Medicine degree from University of Basel, Switzerland and she is a Fellow of the Faculty of Pharmaceutical Medicine in London, UK (FFPM).
Follow Andrea Spezzi:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Ali Parsa
Founder and CEO of Babylon
Ali is an entrepreneur and engineer. He built Circle to become Europe’s largest partnership of clinicians, achieving around £200M in annual revenue, 3000 employees and a successful IPO, all during an economic recession. He was named by The Times as among the 100 global people to watch, and was the recipient of the Royal Award for young entrepreneurs for founding V&G earlier in his career. Ali is a UK Cabinet Office Ambassador and has a PhD in engineering Physics.
Follow Ali Parsa:
About Babylon: Babylon is a world leading, digital-first, value-based care company.
Lana Ghanem
Founder & Managing Director of Hikma Ventures
Lana is managing director at Hikma Ventures which she helped establish in 2015. Lana started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy & Development where she worked on strategic projects across the company’s various functions including strategy, M&A, operations and finance. Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries. Lana holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University.
Follow Lana Ghanem:
About Hikma Ventures: Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.
Mathieu de Beaumont
Co-Founder / Director of Dementech
Co-Founder of Dementech Neurosciences
Follow Mathieu de Beaumont:
About : Neurology & Psychology experts
Michel Rabhi
Founder and Director of Dementech
Owner and Director at Dementech Neurosciences
Follow Michel Rabhi:
About : Neurology & Psychology experts
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Agnieszka Chomka
Co-Founder and Head of R&D of BioMe Oxford
Agnieszka is an intestinal immunologist at the Kennedy Institute for Rheumatology, University of Oxford. Her main research interests focus on the microbial-host interactions in the large intestine. She was awarded the prestigious Wellcome Trust scholarship at the University of Oxford to conduct her research into the role of a tissue-resident regulatory immune cell population in the gut. Agnieszka has published her results in top peer-review research journals.
Follow Agnieszka Chomka:
About BioMe Oxford, Globe Life Sciences: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Fouad Al Noor
Co-Founder & CEO of ThinkSono
Fouad has a masters in Electronic Engineering with Nanotechnology from the University of Southampton. He worked as a research assistant at Imperial College London before joining Entrepreneur First. He wrote his thesis on paper-based medical diagnostics using image processing.
Follow Fouad Al Noor:
About ThinkSono: Cutting edge AI ultrasound software for detection of blood clots (DVT)
Sven Mischkewitz
CTO & Co-Founder of ThinkSono
Sven is an award-winning software engineer from Hasso-Plattner-Institute, Germany. Before joining Entrepreneur First, he worked on annotation tools for brain cells on projects for the Max-Planck-Institute for Brain Research. He focused on the field of Human-Computer-Interaction during his studies.
Follow Sven Mischkewitz:
About ThinkSono: Cutting edge AI ultrasound software for detection of blood clots (DVT)
Clare Cooper
Founder and Vice President of Storm3
Clare Cooper is the Founder and Vice President at Storm3.
Follow Clare Cooper:
About Storm3: Storm3 are a global HealthTech talent marketplace, connecting organizations with the talent to drive their mission.
Silja Litvin
Founder & CEO of PsycApps
I am a London based Psychologist, CEO and Founder of the Mental Health platform PsycApps. The mental health platform is also part of my PhD thesis in clinical psychology at the Ludwig Maximilian University (LMU) of Munich with help of Oxford University College. • In 2013 I finished my Masters in Psychology from LMU majoring in Family and Clinical Psychology. • As aforementioned I am currently completing my postgraduate education as a PhD student of the LMU with help of University College, Oxford. To help raise awareness for both mental well-being in general and our products, I speak at conferences and mental health panels. Being half German, half American, I speak fluent English and German. My French is decent and I understand Italian quite well. Because of my modelling career I am well-traveled, culturally diverse and I am by nature an extroverted people person. Media (1)This position has 1 media
Follow Silja Litvin:
About PsycApps, PsycApps, UCL, Wonder Women Tech: Digital Mental Health Games
Neel Patel
Founder & Chief Executive Officer of ZiO Health
Follow Neel Patel:
About ZiO Health: ZiO Health has developed proprietary pocket-sized technology, bringing lab testing to the point of use.
Dr Vincent Forte
Founder of Forte Medical
Follow Dr Vincent Forte:
About Forte Medical: Forte Medical is a diagnostic center in London, England.
Cameron Shaw
Founder and COO of Virax Biolabs
Cameron Shaw is the founder and Chief Operations Officer at Virax Biolabs.
Follow Cameron Shaw:
About Virax Biolabs: Virax Biolabs is an innovative Biotechnology company focused on the prevention, detection and diagnosis of viral diseases
David Lane
COO and Co-Founder of EProfiler Solutions
Follow David Lane:
About EProfiler Solutions: EProfiler Solutions develops technology solutions to diagnose diseases.
Adrian Hayday
Co-Founder of GammaDelta Therapeutics
Adrian Hayday was trained in biochemistry at Cambridge, and obtained a PhD in molecular virology from London University. He began studying immunology in 1982 at MIT, where he and his colleagues first described the wholly unanticipated T cell receptor gamma chain genes. Since then Professor Hayday has used many parameters to establish that gamma-delta T cells are clearly distinct from conventional T cells. Those parameters include the cells’ responses to different products of a novel gene family expressed at body surfaces, that Professor Hayday and his colleagues identified. He showed that this unique biology allows gamma-delta T cells to make rapid responses to tissue dysreguation, rather than to specific pathogens, and thereby to monitor tissue integrity. This may explain Professor Hayday’s observation that gamma-delta T cell deficiency is associated with a profound susceptibility to skin carcinogens, findings which were instrumental in promoting his and others’ interest in the cells’ clinical application. In other clinical activities, he directed a team describing the human immune response to vaccination and described the unique properties of human autoantibodies. Additionally, he is the lead-investigator of a Wellcome Trust-supported, multi-centre, high-throughput phenotyping screen identifying novel genetic regulators of the immune system. Professor Hayday has authored over 200 papers, of which he is first, last, or corresponding author on over 120, and of which 150 are original research contributions. He has received many awards, including the William Clyde deVaneMedal, Yale College’s highest honour for scholarship and teaching, an honorary fellowship of King’s College London, and the King’s College Business Award, 2008. He was elected to lead the British Society of Immunology (2005-09) and has organized many scientific meetings including the 2014 Gordon Conference in Immunochemistry and Immunobiology, and the scientific programme for the 2012 European Congress of Immunology. He is an elected fellow of the Academy of Medical Sciences and of the Royal Society. He has formally advised many institutions including Institut Pasteur; the Max Planck Institute; Kyoto University, the Wellcome Trust, and Cancer Research UK, whose science committee he chaired for three years. He has participated in many aspects of the biotech/pharmaceutical sector, including membership of the MedImmune SAB, and was a co-founder of ImmunoQure AG before co-founding GammaDelta Therapeutics in 2016.
Follow Adrian Hayday:
About GammaDelta Therapeutics: GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells
Julie Barnes
Founder/ Chief Scientific Officer & Chief Executive Officer of Abcodia
Julie has over 20 years experience of the Pharmaceutical and Biotechnology industry, including 15 years experience of early R&D with GlaxoSmithKline. More recently Julie was director and Chief Scientific Officer at BioWisdom, a healthcare technology company. Her mix of scientific and commercial experience in large pharmaceutical and small start-ups and academic network brings a strong understanding of what is required to successfully lead Abcodia as an ethical and collaborative organisation.
Follow Julie Barnes:
About Abcodia: Abcodia is an innovative biotech company engaged in the validation and discovery of molecular biomarkers.
